Amgen is pushing back against FDA concerns that could remove Tavneos (avacopan) from the market, according to reporting on the company’s request for an independent review. The dispute centers on allegations of safety risks and alleged trial-data manipulation tied to litigation involving the original developer, ChemoCentryx. In parallel, the story highlights how the agency and the company appear to be seeking different outcomes—one focused on withdrawal risk assessment and the other on maintaining the current approval. The outcome will be closely watched by the rare-disease community because it could set a precedent for how regulators treat trial-evidence challenges tied to corporate histories. For patients and partners, the immediate impact is uncertainty around access, while for developers the longer-term effect is a heightened focus on evidentiary integrity and procedural defensibility in post-approval scrutiny.